Sabina Signoretti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4789648/publications.pdf

Version: 2024-02-01

258	32,226	4955 84	4427 172
papers	citations	h-index	g-index

265	265	265	41652
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The landscape of somatic copy-number alteration across human cancers. Nature, 2010, 463, 899-905.	13.7	3,331
2	Renal cell carcinoma. Nature Reviews Disease Primers, 2017, 3, 17009.	18.1	1,727
3	Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine, 2016, 374, 135-145.	13.9	1,040
4	High-throughput oncogene mutation profiling in human cancer. Nature Genetics, 2007, 39, 347-351.	9.4	927
5	Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science, 2018, 359, 801-806.	6.0	898
6	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discovery, 2015, 5, 1164-1177.	7.7	821
7	Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion. Cancer Research, 2005, 65, 3044-3048.	0.4	750
8	The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. Cancer Cell, 2014, 26, 319-330.	7.7	665
9	Essential roles of PI(3)Kâ€“p110Î² in cell growth, metabolism and tumorigenesis. Nature, 2008, 454, 776-779.	13.7	654
10	p63 Is a Prostate Basal Cell Marker and Is Required for Prostate Development. American Journal of Pathology, 2000, 157, 1769-1775.	1.9	538
11	Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN. Molecular and Cellular Biology, 2000, 20, 8969-8982.	1.1	530
12	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Reports, 2018, 23, 313-326.e5.	2.9	523
13	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	7.7	506
14	A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis. Nature Communications, 2019, 10, 1617.	5.8	499
15	Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nature Medicine, 2020, 26, 909-918.	15.2	488
16	SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature, 2011, 470, 269-273.	13.7	462
17	Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nature Genetics, 2018, 50, 1271-1281.	9.4	438
18	Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells. Cell Metabolism, 2014, 19, 795-809.	7.2	411

#	Article	IF	Citations
19	Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer. Clinical Cancer Research, 2005, 11, 3714-3721.	3.2	401
20	Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature, 2002, 419, 162-167.	13.7	390
21	Patterns of Gene Expression and Copy-Number Alterations in von-Hippel Lindau Disease-Associated and Sporadic Clear Cell Carcinoma of the Kidney. Cancer Research, 2009, 69, 4674-4681.	0.4	370
22	Genetic and Functional Studies Implicate HIF1Î± as a 14q Kidney Cancer Suppressor Gene. Cancer Discovery, 2011, 1, 222-235.	7.7	347
23	On-target efficacy of a HIF-2Î± antagonist in preclinical kidney cancer models. Nature, 2016, 539, 107-111.	13.7	341
24	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 519-532.	3.0	328
25	The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell, 2004, 5, 253-261.	7.7	304
26	Landscape of tumor-infiltrating T cell repertoire of human cancers. Nature Genetics, 2016, 48, 725-732.	9.4	288
27	The Requirement for Cyclin D Function in Tumor Maintenance. Cancer Cell, 2012, 22, 438-451.	7.7	284
28	Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate. Science, 2019, 363, 1217-1222.	6.0	281
29	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	9.4	270
30	Activating mTOR Mutations in a Patient with an Extraordinary Response on a Phase I Trial of Everolimus and Pazopanib. Cancer Discovery, 2014, 4, 546-553.	7.7	266
31	Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell, 2021, 39, 649-661.e5.	7.7	263
32	Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget, 2016, 7, 34341-34355.	0.8	258
33	Primary Cutaneous Marginal Zone B-Cell Lymphoma: A Recently Described Entity of Low-Grade Malignant Cutaneous B-Cell Lymphoma. American Journal of Surgical Pathology, 1997, 21, 1307-1315.	2.1	249
34	Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research, 2015, 3, 1158-1164.	1.6	237
35	Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell, 2021, 39, 632-648.e8.	7.7	230
36	Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates. Journal of Clinical Oncology, 2014, 32, 1889-1894.	0.8	229

#	Article	IF	Citations
37	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics, 2018, 50, 206-218.	9.4	229
38	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. Clinical Cancer Research, 2015, 21, 1071-1077.	3.2	217
39	VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nature Cell Biology, 2008, 10, 361-369.	4.6	216
40	LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Molecular Cancer Therapeutics, 2009, 8, 626-635.	1.9	208
41	Animal Models of Human Prostate Cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Research, 2013, 73, 2718-2736.	0.4	203
42	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	3.2	193
43	BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway. Journal of Biological Chemistry, 2000, 275, 39223-39230.	1.6	188
44	Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine. Cell, 2016, 166, 126-139.	13.5	187
45	Role of the Cdc25A phosphatase in human breast cancer. Journal of Clinical Investigation, 2000, 106, 753-761.	3.9	186
46	p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 8105-8110.	3.3	185
47	The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research, 2010, 16, 3628-3638.	3.2	180
48	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Journal of Clinical Oncology, 2016, 34, 3655-3663.	0.8	174
49	Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors. Cell, 2013, 155, 844-857.	13.5	173
50	Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells. Cancer Research, 2004, 64, 8867-8875.	0.4	170
51	Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2007, 5, 379-385.	0.9	168
52	A novel direct activator of <scp>AMPK</scp> inhibits prostate cancer growth by blocking lipogenesis. EMBO Molecular Medicine, 2014, 6, 519-538.	3.3	168
53	pVHL suppresses kinase activity of Akt in a proline-hydroxylationâ€“dependent manner. Science, 2016, 353, 929-932.	6.0	165
54	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154

#	Article	IF	Citations
55	A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. Cancer Cell, 2008, 14, 146-155.	7.7	153
56	Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13379-13386.	3.3	143
57	Identification of Luminal Breast Cancers That Establish a Tumor-Supportive Macroenvironment Defined by Proangiogenic Platelets and Bone Marrowâ€“Derived Cells. Cancer Discovery, 2012, 2, 1150-1165.	7.7	142
58	Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. Journal of Clinical Investigation, 2002, 110, 633-641.	3.9	142
59	Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. Circulation, 2010, 122, 1004-1016.	1.6	139
60	Metabolomic adaptations and correlates of survival to immune checkpoint blockade. Nature Communications, 2019, 10, 4346.	5.8	139
61	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics, 2013, 45, 747-755.	9.4	138
62	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nature Medicine, 2018, 24, 165-175.	15.2	137
63	SQSTM1 Is a Pathogenic Target of 5q Copy Number Gains in Kidney Cancer. Cancer Cell, 2013, 24, 738-750.	7.7	135
64	p63 regulates commitment to the prostate cell lineage. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11355-11360.	3.3	134
65	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nature Genetics, 2013, 45, 739-746.	9.4	134
66	The High-Dose Aldesleukin â€œSelectâ€•Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2015, 21, 561-568.	3.2	133
67	FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis. Cancer Cell, 2010, 18, 472-484.	7.7	127
68	A Working Group Classification of Focal Prostate Atrophy Lesions. American Journal of Surgical Pathology, 2006, 30, 1281-1291.	2.1	123
69	Reciprocal Effects of STAT5 and STAT3 in Breast Cancer. Molecular Cancer Research, 2009, 7, 966-976.	1.5	121
70	Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. Cancer Discovery, 2019, 9, 230-247.	7.7	119
71	Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells. Modern Pathology, 2002, 15, 1302-1308.	2.9	116
72	PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research, 2015, 3, 1308-1315.	1.6	114

#	Article	IF	Citations
73	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery, 2017, 7, 750-765.	7.7	112
74	Does Arterial Spin-labeling MR Imagingâ€“measured Tumor Perfusion Correlate with Renal Cell Cancer Response to Antiangiogenic Therapy in a Mouse Model?. Radiology, 2009, 251, 731-742.	3.6	111
75	Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. Journal of Clinical Oncology, 2020, 38, 63-70.	0.8	109
76	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European Urology, 2017, 72, 557-564.	0.9	108
77	Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1247.	3.4	105
78	Stabilization of Î²-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene, 2002, 21, 4099-4107.	2.6	102
79	Intermediate basal cells of the prostate: In vitro and in vivo characterization. Prostate, 2003, 55, 206-218.	1.2	97
80	Carbonic Anhydrase IX Expression in Renal Neoplasms. American Journal of Clinical Pathology, 2010, 134, 873-879.	0.4	97
81	Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Research, 2002, 62, 89-98.	0.4	97
82	BRAF Mutations in Metanephric Adenoma of the Kidney. European Urology, 2012, 62, 917-922.	0.9	95
83	Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development. PLoS Genetics, 2016, 12, e1006242.	1.5	93
84	The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer. Clinical Cancer Research, 2007, 13, 758s-763s.	3.2	91
85	The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Nonâ€“Clear Cell Renal Cell Carcinoma. Cancer Immunology Research, 2018, 6, 758-765.	1.6	89
86	Vulnerabilities of PTENâ€“TP53-Deficient Prostate Cancers to Compound PARPâ€“PI3K Inhibition. Cancer Discovery, 2014, 4, 896-904.	7.7	88
87	Combination Radiofrequency Ablation with Intratumoral Liposomal Doxorubicin: Effect on Drug Accumulation and Coagulation in Multiple Tissues and Tumor Types in Animals. Radiology, 2005, 235, 469-477.	3.6	84
88	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nature Communications, 2021, 12, 808.	5.8	84
89	Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clearâ€cell renal cell carcinoma receiving vascular endothelial growth factorâ€targeted therapy. BJU International, 2010, 106, 772-778.	1.3	81
90	irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clinical Cancer Research, 2019, 25, 2174-2184.	3.2	80

#	Article	IF	Citations
91	Detection of Clonal T-Cell Receptor Î³ Gene Rearrangements in Paraffin-Embedded Tissue by Polymerase Chain Reaction and Nonradioactive Single-Strand Conformational Polymorphism Analysis. American Journal of Pathology, 1999, 154, 67-75.	1.9	79
92	Androgen-Driven Prostate Epithelial Cell Proliferation and Differentiation in Vivo Involve the Regulation of p27. Molecular Endocrinology, 2001, 15, 765-782.	3.7	77
93	The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma. Clinical Cancer Research, 2013, 19, 5218-5226.	3.2	77
94	Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study. , 2015, 3, 3.		76
95	Combination of Radiofrequency Ablation with Antiangiogenic Therapy for Tumor Ablation Efficacy: Study in Mice. Radiology, 2007, 244, 464-470.	3.6	75
96	Liposomal Doxorubicin Increases Radiofrequency Ablationâ€“induced Tumor Destruction by Increasing Cellular Oxidative and Nitrative Stress and Accelerating Apoptotic Pathways. Radiology, 2010, 255, 62-74.	3.6	75
97	Estrogen Receptor Î² in Prostate Cancer. American Journal of Pathology, 2001, 159, 13-16.	1.9	72
98	p63 in prostate biology and pathology. Journal of Cellular Biochemistry, 2008, 103, 1354-1368.	1.2	72
99	Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells. Cancer Research, 2006, 66, 5723-5728.	0.4	71
100	Phosphorylation of ETS1 by Src Family Kinases Prevents Its Recognition by the COP1 Tumor Suppressor. Cancer Cell, 2014, 26, 222-234.	7.7	71
101	Obligate Roles for p16 Ink4a and p19 Arf -p53 in the Suppression of Murine Pancreatic Neoplasia. Molecular and Cellular Biology, 2002, 22, 635-643.	1.1	68
102	Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy. American Journal of Roentgenology, 2008, 191, 133-139.	1.0	67
103	Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer. Clinical Cancer Research, 2015, 21, 1925-1934.	3.2	67
104	The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis. Genes and Development, 2019, 33, 1718-1738.	2.7	65
105	Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression. PLoS ONE, 2011, 6, e19144.	1.1	64
106	Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poorâ€risk metastatic renal cell carcinoma. Cancer, 2015, 121, 3435-3443.	2.0	64
107	Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling. Molecular Cancer Therapeutics, 2010, 9, 2793-2802.	1.9	63
108	Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma. Clinical Cancer Research, 2014, 20, 1873-1883.	3.2	63

#	Article	IF	Citations
109	Reduced Tumor Growth with Combined Radiofrequency Ablation and Radiation Therapy in a Rat Breast Tumor Model. Radiology, 2005, 235, 81-88.	3.6	60
110	The Glomuvenous Malformation Protein Glomulin Binds Rbx1 and Regulates Cullin RING Ligase-Mediated Turnover of Fbw7. Molecular Cell, 2012, 46, 67-78.	4.5	59
111	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. British Journal of Cancer, 2020, 122, 555-563.	2.9	59
112	Transition from In Situ to Invasive Testicular Germ Cell Neoplasia is Associated with the Loss of p21 and Gain of mdm-2 Expression. Modern Pathology, 2001, 14, 437-442.	2.9	57
113	A constitutively activated form of the p110Î² isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 11002-11007.	3.3	57
114	Identification of CDCP1 as a hypoxia-inducible factor 2Î± (HIF-2Î±) target gene that is associated with survival in clear cell renal cell carcinoma patients. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3483-3488.	3.3	57
115	KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunology Research, 2021, 9, 156-169.	1.6	56
116	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.	1.9	54
117	Melanocytic Nevi of Palms and Soles. American Journal of Surgical Pathology, 1999, 23, 283-287.	2.1	54
118	Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncology, The, 2013, 14, 81-87.	5.1	52
119	Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo. Molecular Cancer, 2015, 14, 119.	7.9	50
120	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research, 2019, 25, 6080-6088.	3.2	50
121	Do Liposomal Apoptotic Enhancers Increase Tumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor Model?. Radiology, 2010, 257, 685-696.	3.6	49
122	Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. International Journal of Hyperthermia, 2011, 27, 527-538.	1.1	49
123	Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. Journal of Clinical Oncology, 2018, 36, 3553-3559.	0.8	49
124	Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 1371-1380.	3.2	49
125	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naÃ¯ve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).. Journal of Clinical Oncology, 2020, 38, 5006-5006.	0.8	48
126	Detection of TCR-Î³ gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. Journal of Cutaneous Pathology, 2000, 27, 228-234.	0.7	47

#	Article	IF	Citations
127	Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. Journal of Pathology, 2001, 193, 200-209.	2.1	47
128	Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models. Radiology, 2006, 240, 82-89.	3.6	47
129	Opposing Effects of Androgen Deprivation and Targeted Therapy on Prostate Cancer Prevention. Cancer Discovery, 2013, 3, 44-51.	7.7	47
130	HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species. Science Signaling, 2019, 12, .	1.6	47
131	Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors. Cancer Immunology Research, 2020, 8, 1075-1084.	1.6	47
132	Collecting duct carcinoma of the kidney is associated withCDKN2Adeletion andSLCfamily gene up-regulation. Oncotarget, 2016, 7, 29901-29915.	0.8	47
133	Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma. Scientific Reports, 2016, 6, 27702.	1.6	46
134	Tumor Vascularity in Renal Masses: Correlation ofÂArterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. Clinical Genitourinary Cancer, 2016, 14, e25-e36.	0.9	44
135	Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 10238-10243.	3.3	43
136	Defining Cell Lineages in the Prostate Epithelium. Cell Cycle, 2006, 5, 138-141.	1.3	42
137	Risk of Bilateral Renal Cell Cancer. Journal of Clinical Oncology, 2009, 27, 3737-3741.	0.8	42
138	Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: Analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1788-1793.	0.8	41
139	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	2.9	40
140	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). Journal of Clinical Oncology, 2022, 40, 2913-2923.	0.8	40
141	GRK3 is essential for metastatic cells and promotes prostate tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1521-1526.	3.3	39
142	RNA-seq Reveals Aurora Kinaseâ€“Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma. Molecular Cancer Research, 2015, 13, 130-137.	1.5	38
143	Tissue biomarkers in renal cell carcinoma: Issues and solutions. Cancer, 2009, 115, 2290-2297.	2.0	36
144	Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 820-824.	2.3	36

#	Article	IF	Citations
145	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine, 2017, 9, .	5.8	36
146	Prostate stem cells: From development to cancer. Seminars in Cancer Biology, 2007, 17, 219-224.	4.3	35
147	Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients. Journal of Pathology, 2011, 225, 212-221.	2.1	35
148	The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?. Future Oncology, 2019, 15, 1683-1695.	1.1	35
149	Adult Renal Cell Carcinoma. Surgical Pathology Clinics, 2015, 8, 587-621.	0.7	33
150	Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma. British Journal of Cancer, 2018, 118, 1238-1242.	2.9	33
151	Treatment selection for patients with metastatic renal cell carcinoma. Cancer, 2009, 115, 2327-2333.	2.0	32
152	Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 2868-2878.	3.2	32
153	Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. Clinical Genitourinary Cancer, 2016, 14, e585-e594.	0.9	31
154	Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications. Journal of Urology, 2017, 198, 817-823.	0.2	31
155	Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2Î±. European Journal of Cancer, 2014, 50, 1531-1540.	1.3	29
156	ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. Science Translational Medicine, 2021, 13, .	5.8	29
157	p63 Promotes Cell Survival through Fatty Acid Synthase. PLoS ONE, 2009, 4, e5877.	1.1	29
158	D-Cyclins Repress Apoptosis in Hematopoietic Cells by Controlling Death Receptor Fas and Its Ligand FasL. Developmental Cell, 2014, 30, 255-267.	3.1	27
159	Cytokeratin15-Positive Basal Epithelial Cells Targeted in Graft-Versus-Host Disease Express a Constitutive Antiapoptotic Phenotype. Journal of Investigative Dermatology, 2007, 127, 106-115.	0.3	26
160	Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions. Clinical Cancer Research, 2008, 14, 3699-3705.	3.2	24
161	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	7.7	24
162	Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma. Histopathology, 2015, 66, 901-904.	1.6	23

#	Article	IF	Citations
163	Gene Transcript Quantitation by Real-Time RT-PCR in Cells Selected by Immunohistochemistry-Laser Capture Microdissection. Diagnostic Molecular Pathology, 2002, 11, 187-192.	2.1	22
164	Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma. , 2020, 8, e001467.		22
165	Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).. Journal of Clinical Oncology, 2019, 37, 548-548.	0.8	21
166	Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget, 0, 7, 41857-41869.	0.8	21
167	MET as a Target in Papillary Renal Cell Carcinoma. Clinical Cancer Research, 2014, 20, 3361-3363.	3.2	20
168	A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes. Clinical Cancer Research, 2021, 27, 4836-4847.	3.2	20
169	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression. Oncotarget, 2017, 8, 103428-103436.	0.8	19
170	Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27Kip1. Journal of Cutaneous Pathology, 2004, 31, 477-482.	0.7	18
171	Pml represses tumour progression through inhibition of mTOR. EMBO Molecular Medicine, 2011, 3, 249-257.	3.3	18
172	Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer. Cancer Research, 2022, 82, 248-263.	0.4	17
173	A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factorâ€targeted therapies. Cancer, 2016, 122, 2389-2398.	2.0	16
174	Anti-CAIX BBÎ¶ CAR4/8 TÂcells exhibit superior efficacy in a ccRCC mouse model. Molecular Therapy - Oncolytics, 2022, 24, 385-399.	2.0	15
175	RET protein expression in papillary renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 900-905.	0.8	14
176	Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma. PLoS Genetics, 2018, 14, e1007679.	1.5	14
177	Loss of LDAH associated with prostate cancer and hearing loss. Human Molecular Genetics, 2018, 27, 4194-4203.	1.4	14
178	p63+ ureteric bud tip cells are progenitors of intercalated cells. JCI Insight, 2017, 2, .	2.3	14
179	Î”Np63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. Human Pathology, 2015, 46, 384-389.	1.1	13
180	Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy. BJU International, 2008, 101, 31-35.	1.3	12

#	Article	IF	Citations
181	Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. European Urology Focus, 2016, 2, 633-639.	1.6	12
182	FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 2159-2168.	3.2	12
183	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clinical Cancer Research, 2022, 28, 831-839.	3.2	12
184	Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 2022, 40, 3633-3641.	0.8	12
185	Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. Clinical Cancer Research, 2022, 28, 4045-4055.	3.2	12
186	Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor <scp>STAT3</scp>. Cancer Cytopathology, 2015, 123, 696-706.	1.4	11
187	Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2016, 14, 304-313.e6.	0.9	11
188	Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 690-696.	1.9	11
189	Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.. Journal of Clinical Oncology, 2019, 37, 4583-4583.	0.8	11
190	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS684-TPS684.	0.8	11
191	Sensitivity ofVHLmutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2120403119.	3.3	11
192	Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3741-E3748.	3.3	10
193	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer, 2021, 21, 904.	1.1	10
194	Identification of ALK Gene Alterations in Urothelial Carcinoma. PLoS ONE, 2014, 9, e103325.	1.1	9
195	Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2016, 34, 545-545.	0.8	9
196	Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8⁺ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2017, 35, 477-477.	0.8	9
197	Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427.. Journal of Clinical Oncology, 2020, 38, 5024-5024.	0.8	9
198	Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. Clinical Cancer Research, 2022, 28, 748-755.	3.2	9

#	Article	IF	Citations
199	Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.. Journal of Clinical Oncology, 2022, 40, 352-352.	0.8	8
200	Renal-cell carcinoma: a step closer to a new classification. Lancet Oncology, The, 2013, 14, 105-107.	5.1	7
201	Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate. PLoS ONE, 2015, 10, e0128489.	1.1	7
202	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2017, 35, TPS4596-TPS4596.	0.8	7
203	Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. Clinical Proteomics, 2009, 5, 37-45.	1.1	6
204	Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.. Journal of Clinical Oncology, 2020, 38, 5023-5023.	0.8	6
205	Blocking PI3K p110Î² Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. Molecular Cancer Research, 2022, 20, 673-685.	1.5	6
206	Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naÃ¯ve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.. Journal of Clinical Oncology, 2022, 40, 288-288.	0.8	6
207	Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma. Journal of Virology, 2011, 85, 5581-5592.	1.5	5
208	Killer immunoglobulin-like receptor (KIR) and KIRâ€“ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunology, Immunotherapy, 2016, 65, 1523-1532.	2.0	5
209	Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 341-348.	0.9	5
210	PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2021, 39, TPS4596-TPS4596.	0.8	5
211	Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs).. Journal of Clinical Oncology, 2019, 37, 103-103.	0.8	5
212	Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 4514-4514.	0.8	5
213	SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).. Journal of Clinical Oncology, 2020, 38, 5002-5002.	0.8	5
214	BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	5
215	Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma. JCO Precision Oncology, 2022, 6, e2100448.	1.5	5
216	Primary effusion lymphoma in HIVâ€infected patients with multicentric Castleman's disease. Journal of Pathology, 2001, 193, 200-209.	2.1	4

#	Article	IF	Citations
217	Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC).. Journal of Clinical Oncology, 2019, 37, 4568-4568.	0.8	4
218	MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data.. Journal of Clinical Oncology, 2020, 38, e19321-e19321.	0.8	4
219	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2019, 37, TPS4597-TPS4597.	0.8	3
220	Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (S/R RCC) to reveal potential determinants of poor prognosis and response to immune checkpoint inhibitors (ICI).. Journal of Clinical Oncology, 2020, 38, 715-715.	0.8	3
221	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS5101-TPS5101.	0.8	3
222	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. Journal of Clinical Oncology, 2022, 40, 4531-4531.	0.8	3
223	Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC). Cancer Research, 2021, 81, 62-62.	0.4	2
224	The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas.. Journal of Clinical Oncology, 2015, 33, 405-405.	0.8	2
225	A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2015, 33, 408-408.	0.8	2
226	Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST.. Journal of Clinical Oncology, 2018, 36, 619-619.	0.8	2
227	Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.. Journal of Clinical Oncology, 2020, 38, 5010-5010.	0.8	2
228	Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2017, 35, 434-434.	0.8	2
229	Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1. Human Pathology: Case Reports, 2018, 11, 19-20.	0.2	1
230	Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib.. Journal of Clinical Oncology, 2013, 31, 370-370.	0.8	1
231	Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort.. Journal of Clinical Oncology, 2015, 33, 4519-4519.	0.8	1
232	Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2015, 33, 422-422.	0.8	1
233	Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival.. Journal of Clinical Oncology, 2016, 34, e23221-e23221.	0.8	1
234	Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT).. Journal of Clinical Oncology, 2016, 34, 485-485.	0.8	1

#	Article	IF	Citations
235	T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade.. Journal of Clinical Oncology, 2016, 34, 501-501.	0.8	1
236	Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression.. Journal of Clinical Oncology, 2017, 35, 4573-4573.	0.8	1
237	Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2017, 35, 513-513.	0.8	1
238	Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, 626-626.	0.8	1
239	A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC).. Journal of Clinical Oncology, 2018, 36, TPS710-TPS710.	0.8	1
240	PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).. Journal of Clinical Oncology, 2020, 38, TPS765-TPS765.	0.8	1
241	Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial.. Journal of Clinical Oncology, 2020, 38, 740-740.	0.8	1
242	In Reply. Oncologist, 2017, 22, 1561-1561.	1.9	0
243	Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma. Clinical Cancer Research, 2019, 25, 4194-4194.	3.2	0
244	Adult Prostate Epithelium Renewal, Stem Cells and Cancer. , 2009, , 231-246.		0
245	Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC. , 2012, , 69-89.		0
246	Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC).. Journal of Clinical Oncology, 2013, 31, 260-260.	0.8	0
247	A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates.. Journal of Clinical Oncology, 2013, 31, 278-278.	0.8	0
248	Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2013, 31, 387-387.	0.8	0
249	Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data.. Journal of Clinical Oncology, 2015, 33, 4560-4560.	0.8	0
250	The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT).. Journal of Clinical Oncology, 2016, 34, 616-616.	0.8	0
251	Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications.. Journal of Clinical Oncology, 2016, 34, 4535-4535.	0.8	0
252	The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2).. Journal of Clinical Oncology, 2017, 35, 4576-4576.	0.8	0

#	Article	IF	Citations
253	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. Journal of Clinical Oncology, 2018, 36, 679-679.	0.8	0
254	PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143).. Journal of Clinical Oncology, 2018, 36, TPS4597-TPS4597.	0.8	0
255	Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2019, 37, 4582-4582.	0.8	0
256	Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A.. Journal of Clinical Oncology, 2020, 38, 729-729.	0.8	0
257	Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation.. Journal of Clinical Oncology, 2022, 40, 569-569.	0.8	0
258	Molecular characterization of the tumor microenvironment in chromophobe renal cell carcinoma (ChRCC) and related oncocytic neoplasms.. Journal of Clinical Oncology, 2022, 40, 4549-4549.	0.8	0